A
Acumen Pharmaceuticals, Inc. (ABOS)
NMS – Real vaqt narxi. Valyuta: USD
2.48
-0.09 (-3.50%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
2.48
-0.09 (-3.50%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Acumen Pharmaceuticals, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Altsgeymer kasalligini davolash uchun mo'ljallangan terapiyalarni ishlab chiqadi. Kompaniya toksik eruvchan amiloid beta oligomerlarini maqsad qilib olingan immünoterapiya dori nomzodi, sabirnetug (ACU193)ni rivojlantirishga qaratilgan, u 2-bosqichdagi ALTITUDE-AD klinik sinovidan o'tmoqda. Acumen Pharmaceuticals, Inc. Sabirnetugning teri osti shaklini ishlab chiqish bo'yicha Halozyme, Inc. bilan hamkorlik va litsenziyalash shartnomasiga ega, shuningdek, Altsgeymer kasalligini davolash uchun Aß oligomerlariga mo'ljallangan miyaga yaxshilangan yetkazib berish terapiyasini ishlab chiqish bo'yicha JCR Pharmaceuticals Co. Ltd bilan hamkorlik qiladi. Kompaniya 1996 yilda tashkil etilgan va Massachusets shtatining Nyuton shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Amy Schacterle Ph.D. | Chief Regulatory Officer & Head of Quality |
| Dr. James Doherty Ph.D. | President & Chief Development Officer |
| Dr. Laura Rosen M.D., Ph.D. | Senior Vice President of Clinical Development |
| Ms. Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-23 | DEFA14A | defa14a2026.htm |
| 2026-03-30 | CORRESP | filename1.htm |
| 2026-03-26 | 8-K | abos-20260326.htm |
| 2026-03-26 | 10-K | abos-20251231.htm |
| 2026-03-16 | 8-K | abos-20260313.htm |
| 2026-01-12 | 8-K | abos-20260112.htm |
| 2025-11-12 | 8-K | abos-20251112.htm |
| 2025-11-10 | 8-K | abos-20251106.htm |
| 2025-08-12 | 8-K | abos-20250812.htm |
| 2025-08-12 | 10-Q | abos-20250630.htm |